Adam Chill Biography and Net Worth

Director of Mustang Bio


Mr. Chill has served as a member of Mustang’s Board of Directors since June 2017. Mr. Chill is the President of and a Portfolio Manager at Kingsbrook Partners LP, an alternative asset management firm he co-founded in March 2009. From February 2001 to March 2009, Mr. Chill was a Portfolio Manager and Managing Director at Highbridge Capital Management, LLC, an alternative asset management firm owned by J.P. Morgan Asset Management. At Highbridge, Mr. Chill was responsible for structuring, negotiating and monitoring Highbridge’s portfolio of structured investments in public and private companies worldwide. From April 2000 to February 2001, Mr. Chill worked at Angelo, Gordon & Co., an alternative asset management firm. From October 1992 to April 2000, Mr. Chill was a corporate attorney specializing in securities and mergers and acquisitions at Stroock & Stroock & Lavan LLP. Mr. Chill serves as Vice President and a member of the Executive Committee of the American Friends of Shalva, the Association for Mentally and Physically Challenged Children in Israel. Mr. Chill received his B.A., magna cum laude, from Yeshiva University and his J.D. from Columbia University School of Law, where he was a Harlan Fiske Stone Scholar.

What is Adam J. Chill's net worth?

The estimated net worth of Adam J. Chill is at least $161.33 as of December 30th, 2025. Mr. Chill owns 375 shares of Mustang Bio stock worth more than $161 as of October 9th. This net worth estimate does not reflect any other investments that Mr. Chill may own. Learn More about Adam J. Chill's net worth.

How do I contact Adam J. Chill?

The corporate mailing address for Mr. Chill and other Mustang Bio executives is 95 Sawyer RD, Suite 110, Waltham, MA, 02453. Mustang Bio can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on Adam J. Chill's contact information.

Has Adam J. Chill been buying or selling shares of Mustang Bio?

Adam J. Chill has not been actively trading shares of Mustang Bio over the course of the past ninety days. Most recently, Adam J. Chill sold 4 shares of the business's stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $0.95, for a transaction totalling $3.80. Following the completion of the sale, the director now directly owns 375 shares of the company's stock, valued at $356.25. Learn More on Adam J. Chill's trading history.

Who are Mustang Bio's active insiders?

Mustang Bio's insider roster includes Brian Achenbach (SVP), Adam Chill (Director), and Manuel Litchman (CEO). Learn More on Mustang Bio's active insiders.

Are insiders buying or selling shares of Mustang Bio?

In the last twelve months, Mustang Bio insiders bought shares 1 times. They purchased a total of 247 shares worth more than $237.12. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 251 shares worth more than $240.92. The most recent insider tranaction occured on December, 30th when Director David Jin bought 247 shares worth more than $237.12. Insiders at Mustang Bio own 4.0% of the company. Learn More about insider trades at Mustang Bio.

Information on this page was last updated on 12/30/2025.

Adam J. Chill Insider Trading History at Mustang Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/30/2025Sell4$0.95$3.80375View SEC Filing Icon  
See Full Table

Adam J. Chill Buying and Selling Activity at Mustang Bio

This chart shows Adam J. Chill's buying and selling at Mustang Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mustang Bio Company Overview

Mustang Bio logo
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Read More

Today's Range

Now: $0.42
Low: $0.38
High: $0.43

50 Day Range

MA: $0.54
Low: $0.42
High: $0.61

2 Week Range

Now: $0.42
Low: $0.38
High: $1.81

Volume

82,313 shs

Average Volume

108,394 shs

Market Capitalization

$3.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09